Market Overview

Jefferies Maintains Buy, $31 PT on Body Central


Jefferies reiterates its Buy rating and $31 price target on Body Central (NASDAQ: BODY) on positive pre-announcement for the fourth quarter.

Jefferies says, "BODY pre-announced 4Q sales numbers ahead of its presentation at the ICR conference later this week. Topline was better than expected and the company raised its EPS outlook to the high end of the prior range. We view this news very positively and remain buyers of this stock, especially given the current cheap valuation for a high growth name."

BODY closed at $23.15 per share on Monday.

Posted-In: JefferiesReiteration Pre-Market Outlook Markets Analyst Ratings


Related Articles (BODY)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→